Authors

Latest:

Cota-Watson Effort Aims at Optimal Cost Margins as Well as Improved Care

Investigators at Cota, a New York medical data analytics company, are taking further strides toward putting their growing knowledge of variance in care to work in the clinical setting.

Brandon Scalea

Latest:

BTK Inhibitors Show Continued Promise in CLL

Brian T. Hill, MD, PhD, highlights the latest data with BTK inhibitors in chronic lymphocytic leukemia.

Brandon Tom, PharmD

Latest:

In-Office Dispensing Is Better Value

With increased competition, the challenge in-office dispensing practices now face is to prove the value of what they do.

Brandon Weckbaugh, MD

Latest:

Dr. Weckbaugh on the LIBRETTO-001 Trial in NSCLC

Brandon Weckbaugh, MD, an oncology fellow at the University of Missouri-Kansas City, discusses the results of the LIBRETTO-001 trial in the patients with non–small cell small cancer (NSCLC).

Brant Inman, MD

Latest:

Dr. Inman on Immunotherapy Combinations in Bladder Cancer

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center, discusses novel immunotherapy combinations for patients with bladder cancer.

Breanne E. Terakedis, MD

Latest:

The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment Recommendations

Researchers evaluate the role of magnetic-resonance imaging in the clinical staging of prostate cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.

Breast Cancer Broadcast/News

Breelyn A. Wilky, MD

Breelyn Wilky, MD, is the director of Sarcoma Medical Oncology, The Cheryl Bennet and McNeilly Family Endowed Chair in Sarcoma Research, director of Sarcoma Medical Oncology, and deputy associate director for Clinical Research at the University of Colorado Cancer Center – Anschutz Medical Campus.

Latest:

Dr Wilky on the Role of Personalized Therapy in GIST

Breelyn Wilky, MD, details personalized therapy approaches for the treatment of patients with GIST.

Breelyn Wilky, MD

Latest:

Next-Generation Treatment Strategies for GIST: Evaluating Combination Therapies and Mutation-Specific Approaches

Experts discuss the preliminary results of the PEAK study on the combination of bezuclastinib and sunitinib in second-line gastrointestinal stromal tumors (GIST), its potential to address heterogeneous resistance mutations, and how mutation-specific, biomarker-driven approaches in ongoing trials like INSIGHT may shift the treatment paradigm compared with traditional line-of-therapy strategies.

Bren Simon Cancer Center

Brendan Curley, DO, MPH

Latest:

Canine Caring: A Therapy Dog for Cancer Patients

Princess Danger was never intended to be a therapy dog. She came into our home as a pet, a goofball who immediately stole our hearts. The funny thing is that she not only stole our hearts, but that of anyone who met her.

Brendon M. Stiles, MD

Latest:

Cost-Effectiveness and Closing Perspectives in Early-Stage NSCLC

Panelists discuss how financial toxicity and cost-effectiveness analyses highlight the importance of appropriate patient selection for perioperative immunotherapy, while emphasizing that multidisciplinary care and patient involvement remain essential for optimal outcomes.

Brian A. Moore, MD, FACS

Latest:

Remote Monitoring Enhances Care for Patients With Head and Neck Cancer

If clinicians can identify complications earlier and take appropriate prophylactic or therapeutic measures, treatment plan adherence and outcomes may be improved for patients with head and neck cancer.

Brian A. Van Tine, MD, PhD

Brian A. Van Tine, MD, PhD, is a professor of medicine in the John T. Milliken Department of Medicine Division of Oncology at the Washington University School of Medicine

Latest:

Dr Van Tine on Investigating Olaparib Plus Temozolomide vs Investigator’s Choice of Therapy in Advanced Uterine Leiomyosarcoma

Brian A. Van Tine, MD, PhD, discusses the use of olaparib plus temozolomide in advanced uterine leiomyosarcoma following progression on chemotherapy.

Brian A. Van Tine, MD, PhD, Siteman Cancer Center

Brian Baumann, MD

Latest:

Dr. Brian Baumann on the Impact of Skin Cream Use Prior to Radiation

Brian Baumann, MD, medical oncologist, University of Pennsylvania, discusses the impact of skin creams on radiation.

Brian D. Crompton, MD

Latest:

Dr. Crompton on the Potential for Liquid Biopsies in Pediatric Sarcomas

Brian D. Crompton, MD, physician, Pediatric Hematology/Oncology, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses the potential of liquid biopsies in the treatment of pediatric patients with sarcoma.

Brian F. Chapin, MD

Latest:

Dr. Chapin on Impact of Active Surveillance in Field of Prostate Cancer

Brian F. Chapin, MD, assistant professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses impact of active surveillance in the field of prostate cancer.

Brian G. M. Durie, MD

Latest:

Dr. Durie on a More Sensitive Automated Flow Cytometry MRD Test

Brian G.M. Durie, MD, chairman, International Myeloma Foundation, hematologist/oncologist, Cedars-Sinai Medical Center, Los Angeles, California, discusses a more sensitive automated flow cytometry minimal residual disease (MRD) test.

Brian G.M. Durie, MD, Robert J. Kreitman, MD

Latest:

ASH Interview Series

The December issue of Oncology & Biotech News featured highlights from the 51st American Society of Hematology (ASH) Annual Meeting and Exposition. We wrap up our ASH coverage this month with interviews on multiple myeloma with Brian G.M. Durie, MD, medical director and co-founder of the International Myeloma Foundation; chronic lymphocytic leukemia (CLL) with Robert J. Kreitman, MD, from the National Cancer Institute; and chronic myeloid leukemia (CML) with Francis J. Giles, MD, Cancer Therapy and Research Center at The University of Texas Health Science Center in San Antonio.